A Study of LY3209590 in Participants With Type 2 Diabetes

I8H-MC-BDCB -

This study will evaluate the safety and tolerability of LY3209590 when given by injection under the skin to participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels.

Trial Summary

Age Range
18 - 70 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Insulin Glargine, LY3209590
Could I receive a Placebo?
No
Enrollment Goal
70
Trial Dates
Jan 3, 2018 - Oct 3, 2018
How long will I be in the trial?
Your participation could last about 17 weeks and include up to 10 visits to the study center.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.